Natera CEO on Cancer Recurrence Detection and Genetic Testing Technology

Natera's Role in Cancer Care

• 💡 Natera is a leading genetic testing company specializing in detecting extremely small quantities of DNA.
• 🚀 The company is celebrating 10 years since going public and has a market capitalization of approximately $22 billion.
• ✅ Natera is cash flow positive and has processed over 12 million tests.

Signatera: Early Cancer Recurrence Detection

• 🎯 Signatera is Natera's specialized test for detecting cancer recurrence up to two years in advance of imaging.
• 🧬 The technology works by identifying a unique genetic signature from a patient's tumor DNA.
• 🩸 This signature is then used to detect tiny fragments of tumor DNA circulating in the patient's blood, indicating recurrence.
• ⚠️ This method addresses the significant problem of disease recurrence, which affects 20-50% of patients.

How the Technology Works

• 🔍 The process involves sequencing the patient's tumor DNA and their germline DNA to find differences.
• 🧬 These differences highlight the specific genetic variants driving the cancer.
• 🔬 By comparing the tumor's genetic imprint to the patient's normal cells, Natera can identify unique cancer markers.

Broader Applications and Market

• 🩺 Beyond cancer, Natera deploys its technology in organ health to detect organ rejection before biopsy and in prenatal care for early pregnancy abnormality detection.
• 💰 The total addressable market for Natera's broad portfolio is estimated at $50 billion, with the MRD segment alone valued at $20 billion.
• 🏥 Natera works with most insurance plans, and patients typically have minimal out-of-pocket costs due to patient assistance programs.